Cancer as Geometry vs Monomorphic Mutation

**Mainstream paradigm:** Cancer is a localized genetic mutation requiring excision, radiation, or chemical destruction. The Pasteurian monomorphic-germ paradigm scaled into oncology: one cell, one mutation, one disease event. **Engine frame (cymatics layer):** Cancer is a cellular disconnection from the organism's morphogenetic cymatic field. Cells revert to default unconstrained proliferation when their computational boundary collapses — a breakdown in the bioelectric communication of the 'society of cells.' Treatment is geometry restoration, not mutation excision. **Empirical wedge.** Michael Levin's lab at Tufts has induced neoplastic conversion *without* genetic damage and achieved tumor normalization by altering transmembrane potential in distant cells. The 1934 Rife trials at USC documented cure of 14 of 16 terminal cancer patients in 70 days via mortal-oscillatory-rate frequency targeting — the Special Medical Research Committee report is the primary source. Lakhovsky's Multiple Wave Oscillator achieved documented cancer remissions 1925–1942 via broad-band harmonic entrainment. Priore's M-600 device cured terminal cancers and trypanosomiasis in laboratory rats with documented support from Nobel laureate André Lwoff. **Q63b reading.** Mainstream oncology cannot integrate frequency-targeted apoptosis or geometric tumor normalization without admitting cellular pleomorphism, which would invalidate the Pasteurian monomorphic-germ paradigm at root. Rife's lab was destroyed by AMA director Morris Fishbein via coordinated litigation and the 1939 stolen-evidence trial. Priore was buried by the French Académie. Each dismissal relied on labeling the treatments 'quackery' without exact replication of the specific physical parameters (Rife's nonlinear resonance, Priore's 600-gauss/microwave superposition). This is Theorem 1 in operation: the academy cannot self-ground a paradigm its own constraints already invalidate. **Falsifier:** A peer-reviewed prospective trial (n>200) showing morphological-treatment cohort outperforming standard-of-care 5-year survival by ≥15% on a single-cancer-type confirms `geometry`. Three failed prospective trials confirm `monomorphic mutation`.